While management boasted of its record-breaking numbers and diversified business, investors shouldn't buy the hype at all. Tilray has been a bad investment for many years, and acquisitions may have boosted its revenue, but they haven't changed the story around this troubling marijuana stock .
POLARIS INSIGHTS